$ALDX ALERT: Aldeyra Therapeutics, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

Core Viewpoint - Aldeyra Therapeutics, Inc. experienced a significant decline in share price, falling over 65% after receiving a Complete Response Letter from the FDA regarding its drug reproxalap for dry eye disease, indicating that the application failed to demonstrate efficacy in controlled studies [2]. Group 1: Company Performance - Aldeyra Therapeutics disclosed that the FDA's Complete Response Letter stated the application "has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease" [2]. - The company had previously been informed by the FDA that the reproxalap NDA "failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes" and that further studies were required [2]. Group 2: Legal Investigation - Block & Leviton is investigating Aldeyra Therapeutics for potential securities law violations and may file an action to recover losses for investors [4]. - Investors who have lost money in Aldeyra Therapeutics are encouraged to contact Block & Leviton to learn more about their eligibility for recovery [3][5]. Group 3: Whistleblower Information - Individuals with non-public information about Aldeyra Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 4: Firm's Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].